Published In a groundbreaking partnership, the Faculty of Medicine Siriraj Hospital has joined forces with AstraZeneca Thailand on the project “Initiatives for Genetic-Related Cancers and Precision Oncology” to advance precision medicine in cancer treatment. The collaboration encompasses academic support for the development and expansion of genomic testing capabilities for various cancer types such as breast cancer, ovarian cancer, and other cancers, adhering to international quality standards. Notably, Siriraj Genomics, Thailand’s first and only laboratory, is equipped to conduct homologous recombination deficiency (HRD) testing, aiding in predicting responses to PARP inhibitors for ovarian cancer patients.
Furthermore, the collaboration extends to the development of a hereditary cancer risk assessment system, facilitating family transmission of genetic information. The initiative also focuses on educating and training genetic counselors for cancer patients, disseminating knowledge on genetic factors in different cancer types, emphasizing the importance of genetic cancer screening, and promoting cancer prevention in individuals with genetic mutations. This partnership aims to enhance public understanding of the significance of genomics and cancer, ultimately fostering widespread precision medicine in Thailand.
The establishment of Siriraj Genomics, under the Dean’s Office, serves as a comprehensive technological hub for genomic research, education, and clinical services within the Faculty of Medicine Siriraj Hospital. Additionally, the center plays a pivotal role as the representative of Siriraj in coordinating and participating in the Genomics Thailand project. This national endeavor aims to decode the genetic information of 50,000 Thai individuals, with the active involvement of approximately 10,000 volunteers through the Faculty of Medicine Siriraj Hospital.
